0

<< Four Evolving Strategies In The Emergent Treatment Of Acute Ischemic Stroke (Stroke CME)

References

TOC Will Appear Here

References

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study will be included in bold type following the reference, where available. In addition, the most informative references cited in this paper, as determined by the authors, are noted by an asterisk (*) next to the number of the reference.

  1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948. (Statistical update)
  2. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29(2):415-421. (Retrospective; 1000 patients)
  3. Thurman RJ, Jauch EC. Acute ischemic stroke: emergent evaluation and management. Emerg Med Clin N America. 2002;20(3):609-630. (Review)
  4. * NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM. 1995;333:1581-1587. (Prospective randomized placebo controlled phase III trial, 624 patients)
  5. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119(1):107-115. (Prospective; 323,000 patients)
  6. Lellis JC, Brice JH, Evenson KR, et al. Launching online education for 911 telecommunicators and EMS personnel: experiences from the North Carolina Rapid Response to Stroke Project. Prehosp Emerg Care. 2007;11(3):298-306. (Prospective educational intervention)
  7. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;23.
  8. Heiss WD. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer award 2011. Cerebrovasc Dis. 2011;32(4):307-320. (Lecture)
  9. Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(6):427-432. (Retrospective eview for prognosis prediction)
  10. Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57(3):474-480. (Retrospective review for prognosis prediction)
  11. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003;34(1):122-126. (Retrospective review for prognosis prediction)
  12. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59(5):669-674.
  13. Ford GA, Ahmed N, Azevedo E, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41(11):2568-2574.
  14. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309. (Observational registry; 664 patients)
  15. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28(5):957-960. (Retrospective reanalysis; 620 patients)
  16. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774. (Meta-analysis; 2775 patients)
  17. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438-441. (Retrospective reanalysis; 800 patients)
  18. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017-1025. (Prospective randomized placebo controlled phase III trial; 620 patients)
  19. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245-1251. (Prospective randomized placebo controlled phase III trial; 800 patients)
  20. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282(21):2019-2026. (Prospective randomized placebo-controlled phase III trial; 613 patients)
  21. Ringleb PA, Schellinger PD, Schranz C, et al. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke. 2002;33(5):1437-1441. (Retrospective review for prognosis prediction)
  22. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34(2):464-467. (Retrospective review for prognosis prediction)
  23. Kent DM, Selker HP, Ruthazer R, et al. The stroke--thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37(12):2957-2962. (Retrospective review for prognosis prediction)
  24. * Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. (Prospective randomized placebo-controlled phase III trial; 821 patients)
  25. * del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009. 40(8):2945-2948. (Guideline)
  26. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a meta-analysis. Stroke. 2009;40(7):2438-2441. (Meta-analysis)
  27. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;23:23. (Randomized controlled trial; 3035 patients)
  28. * Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. May 23, 2012. (Epub ahead of print) (Meta-analysis; 7012 patients)
  29. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587. (Prospective randomized double-blind placebo-controlled clinical trial; 624 patients)
  30. * Adams HP, Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655-1711. (Consensus statement; guidelines)
  31. Truwit CL, Barkovich AJ, Gean-Marton A, et al. Loss of the insular ribbon: another early CT sign of acute middle cerebral artery infarction. Radiology. 1990;176(3):801-806. (Retrospective, prospective case series; 27 patients
  32. Tomura N, Uemura K, Inugami A, et al. Early CT finding in cerebral infarction: obscuration of the lentiform nucleus. Radiology. 1988;168(2):463-467. (Retrospective; 25 patients)
  33. Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286(22):2830-2838.
  34. Pressman BD, Tourje EJ, Thompson JR. An early CT sign of ischemic infarction: increased density in a cerebral artery. AJR Am J Roentgenol. 1987;149(3):583-586. (Case series; 19 patients)
  35. Schuknecht B, Ratzka M, Hofmann E. The “dense artery sign”--major cerebral artery thromboembolism demonstrated by computed tomography. Neuroradiology. 1990;32(2):98-103. (Retrospective; 121 patients)
  36. * Ledezma CJ, Wintermark M. Multimodal CT in stroke imaging: new concepts. Radiol Clin North Am. 2009;47(1):109-116. (Review)
  37. Rowley HA. The four Ps of acute stroke imaging: parenchyma, pipes, perfusion, and penumbra. AJNR Am J Neuroradiol. 2001;22(4):599-601. (Editorial)
  38. Pomerantz SR, Harris GJ, Desai HJ, et al. Computed tomography angiography and computed tomography perfusion in ischemic stroke: A step-by-step approach to image acquisition and three-dimensional postprocessing. Semin Ultrasound CT MR. 2006;27(3):243-270. (Review)
  39. Kloska SP, Nabavi DG, Gaus C, et al. Acute stroke assessment with CT: do we need multimodal evaluation? Radiology. 2004;233(1):79-86. (Prospective; 44 patients)
  40. Gupta R, Jones SE, Mooyaart EA, et al. Computed tomographic angiography in stroke imaging: fundamental principles, pathologic findings, and common pitfalls. Semin Ultrasound CT MR. 2006;27(3):221-242. (Review)
  41. Schuknecht B. Latest techniques in head and neck CT angiography. Neuroradiology. 2004;46 Suppl 2:s208-s213. (Review)
  42. Mukherjee S, Raghavan P, Phillips CD. Computed tomography perfusion: acute stroke and beyond. Semin Roentgenol. 2010;45(2):116-125. (Review)
  43. Wintermark M, Reichhart M, Cuisenaire O, et al. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke. 2002;33(8):2025-2031. (Prospective series; 13 patients)
  44. Wintermark M, Meuli R, Browaeys P, et al. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology. 2007;68(9):694-697. (Retrospective; 47 patients)
  45. Konstas AA, Goldmakher GV, Lee TY, et al. Theoretic basis and technical implementations of CT perfusion in acute ischemic stroke, part 1: theoretic basis. AJNR Am J Neuroradiol. 2009;30(4):662-668. (Review)
  46. Konstas AA, Goldmakher GV, Lee TY, et al. Theoretic basis and technical implementations of CT perfusion in acute ischemic stroke, part 2: technical implementations. AJNR Am J Neuroradiol. 2009;30(5):885-892. (Review)
  47. Wintermark M, Reichhart M, Thiran JP, et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol. 2002;51(4):417-432. (Prospective; 22 patients)
  48. * Gonzalez RG. Imaging-guided acute ischemic stroke therapy: from “time is brain” to “physiology is brain.” AJNR Am J Neuroradiol. 2006;27(4):728-735. (Review)
  49. Schumacher HC, Bateman BT, Boden-Albala B, et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample, 1999 to 2004. Ann Emerg Med. 2007;50(2):99-107. (Retrospective observational cohort; 366,194 patients)
  50. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke. 2005;36(3):602-606. (Prospective; 135 patients)
  51. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurology. 2009;8(2):141-150. (Randomized controlled trial; 193 patients)
  52. * Konstas AA, Wintermark M, Lev MH. CT perfusion imaging in acute stroke. Neuroimaging Clin N Am. 2011;21(2):215-238. (Review)
  53. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254-2258. (Retrospective; 388 patients)
  54. * Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke. 2006;37(4):979-985. (Prospective multicenter trial; 130 patients)
  55. Schaefer PW, Roccatagliata L, Ledezma C, et al. First-pass quantitative CT perfusion identifies thresholds for salvageable penumbra in acute stroke patients treated with intra-arterial therapy. AJNR Am J Neuroradiol. 2006;27(1):20-25. (Prospective; 14 patients)
  56. Mishra NK, Albers GW, Davis SM, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010;41(1):e25-e33. (Meta-analysis; 502 patients)
  57. Palomaki H, Muuronen A, Raininko R, et al. Administration of nonionic iodinated contrast medium does not influence the outcome of patients with ischemic brain infarction. Cerebrovasc Dis. 2003;15(1-2):45-50. (Prospective; 205 patients)
  58. Lima FO, Lev MH, Levy RA, et al. Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy. AJNR Am J Neuroradiol. 2010;31(5):817-821. (Retrospective; 575 patients)
  59. Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics. 2004;24 Suppl 1:s3-s10. (Review)
  60. Wintermark M, Albers GW, Alexandrov AV, et al. Acute stroke imaging research roadmap. Stroke. 2008;39(5):1621-1628. (Guidelines; position statement)
  61. Mackey J, Khatri P, Broderick JP, et al. Increasing use of CT angiography in interventional study sites: the IMS III experience. AJNR Am J Neuroradiol. 2010;31(3):E34. (Survey; 53 study sites)
  62. Leiva-Salinas C, Wintermark M. The future of stroke imaging: what we need and how to get to it. Stroke. 2010;41(10 Suppl):s152-s153. (Letter)
  63. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015-1020. (Prospective; 2165 patients)
  64. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59(6):862-867. (Prospective; 60 patients)
  65. Janjua N, Alkawi A, Suri MF, et al. Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. AJNR Am J Neuroradiol. 2008;29(2):253-558. (Retrospective; 100 patients)
  66. Saqqur M, Molina CA, Salam A, et al. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke. 2007;38(1):69-74. (Prospective; 374 patients)
  67. Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14(1):3-13. (Prospective; 93 patients)
  68. Arnold M, Nedeltchev K, Mattle HPet al. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry. 2003;74(6):739-742. (Prospective; 24 patients)
  69. Jansen O, von Kummer R, Forsting M, et al. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR Am J Neuroradiol. 1995;16(10):1977-1986. (Prospective; 32 patients)
  70. Sorimachi T, Fujii Y, Tsuchiya N, et al. Recanalization by mechanical embolus disruption during intra-arterial thrombolysis in the carotid territory. AJNR Am J Neuroradiol. 2004;25(8):1391-1402. (Prospective; 23 patients)
  71. Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke. 2002;33(7):1821-1826. (Retrospective; 18 patients)
  72. * Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38(3):967-973. (Meta-analysis; 2066 patients)
  73. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke. 1998;29(1):4-11. (Randomized controlled trial; 46 patients)
  74. * Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA. 1999;282(21):2003-2011. (Randomized controlled trial; 180 patients)
  75. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36(7):1432-1438. (Prospective; 151 patients)
  76. Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1 study of mechanical embolus removal in cerebral ischemia. Stroke. 2004;35(12):2848-2854. (Prospective; 30 patients)
  77. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi-MERCI trial. Stroke. 2008;39(4):1205-1212. (Prospective; 164 patients)
  78. Bose A, Henkes H, Alfke K, et al. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008;29(7):1409-1413. (Prospective; 23 patients)
  79. Natarajan SK, Karmon Y, Snyder KV, et al. Prospective acute ischemic stroke outcomes after endovascular therapy: a real-world experience. World Neurosurg. 2010;74(4-5):455-464. (Prospective; 213 patients)
  80. Meyers PM, Schumacher HC, Higashida RT, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2009;119(16):2235-2249. (Guideline paper)
  81. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35(4):904-911.
  82. * IMS Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38(7):2127-2135. (Prospective; 81 patients)
  83. Tomsick T, Broderick J, Carrozella J, et al. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008;29(3):582-587.(Prospective; 29 patients)
  84. Khatri P, Hill MD, Palesch YY, et al. Methodology of the Interventional Management of Stroke III trial. Int J Stroke. 2008;3(2):130-137.
  85. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol. 2006;27(6):1177-1182. (Prospective; 111 patients)
  86. Nogueira RG, Schwamm LH, Hirsch JA. Endovascular approaches to acute stroke, part 1: drugs, devices, and data. AJNR Am J Neuroradiol. 2009;30(4):649-661. (Review)
  87. Penumbra Pivotal Stroke Trial I. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40(8):2761-2768. (Prospective; 125 patients)
  88. Tarr R, Hsu D, Kulcsar Z, et al. The POST trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J Neurointerv Surg. 2010;2(4):341-344. (Retrospective; 157 patients)
  89. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technique and a preliminary report of its application. Circulation. 1964;30:654-670. (Case series)
  90. Nakano S, Yokogami K, Ohta H, et al. Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion. AJNR Am J Neuroradiol. 1998;19(4):767-772. (Prospective; 10 patients)
  91. Qureshi AI, Siddiqui AM, Suri MF, et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery. 2002;51(5):1319-1327; discussion 27-29. (Prospective; 19 patients)
  92. Yoneyama T, Nakano S, Kawano H, et al. Combined direct percutaneous transluminal angioplasty and low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion. AJNR Am J Neuroradiol. 2002;23(2):277-281. (Prospective; 15 patients)
  93. Abou-Chebl A, Bajzer CT, Krieger DW, et al. Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. Stroke. 2005;36(10):2286-2288. (Prospective; 12 patients)
  94. Nakano S, Iseda T, Yoneyama T, et al. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke. 2002;33(12):2872-2876. (Open, prospective with retrospective controls; 140 patients)
  95. Ueda T, Sakaki S, Nochide I, et al. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke. 1998;29(12):2568-2574. (Prospective; 13 patients)
  96. Levy EI, Ecker RD, Hanel RA, et al. Acute M2 bifurcation stenting for cerebral infarction: lessons learned from the heart: technical case report. Neurosurgery. 2006;58(3):E588. (Case report)
  97. Levy EI, Ecker RD, Horowitz MB, et al. Stent-assisted intracranial recanalization for acute stroke: early results. Neurosurgery. 2006;58(3):458-463. (Retrospective; 19 patients)
  98. Fitzsimmons BF, Becske T, Nelson PK. Rapid stent-supported revascularization in acute ischemic stroke. AJNR Am J Neuroradiol. 2006;27(5):1132-1134. (Case report)
  99. Levy EI, Mehta R, Gupta R, et al. Self-expanding stents for recanalization of acute cerebrovascular occlusions. AJNR Am J Neuroradiol. 2007;28(5):816-822. (Retrospective; 18 patients)
  100. * Levy EI, Siddiqui AH, Crumlish A, et al. First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke). Stroke. 2009;40(11):3552-3556. (Prospective; 20 patients)
  101. Mocco J, Hanel RA, Sharma J, et al. Use of a vascular reconstruction device to salvage acute ischemic occlusions refractory to traditional endovascular recanalization methods. J Neurosurg. 2010;112(3):557-562. (Retrospective; 20 patients)
  102. Kelly ME, Furlan AJ, Fiorella D. Recanalization of an acute middle cerebral artery occlusion using a self-expanding, reconstrainable, intracranial microstent as a temporary endovascular bypass. Stroke. 2008;39(6):1770-1773. (Case report)
  103. Hauck EF, Mocco J, Snyder KV, et al. Temporary endovascular bypass: a novel treatment for acute stroke. AJNR Am J Neuroradiol. 2009;30:1532-1533. (Case report)
  104. Concentric Medical. TREVO enrollment completion. Available at: http://www.concentric-medical.com/home. Accessed December 8, 2011. (Prospective; 36 patients)
  105. * Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA. 2000;283(23):3102-3109. (Guideline paper)
  106. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36(7):1597-1616. (Guideline paper)
  107. * Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the Brain Attack Coalition. Stroke. 2011;42(9):2651-2665. (Guideline paper)
  108. Alberts MJ. Preventing death one stroke at a time. JAMA. 2011;305(4):408-409. (Editorial)
  109. Leifer D, Bravata DM, Connors JJ 3rd, et al. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to Brain Attack Coalition comprehensive stroke center recommendations: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(3):849-877. (Guideline)
  110. The Joint Commission. Final certification eligibility criteria for Comprehensive Stroke Centers (CSC). 2012; published online ahead of print. Available at: http://www.jointcommission.org/certification/advanced_certification_comprehensive_stroke_centers.aspx Accessed May 30, 2012.
  111. Lattimore SU, Chalela J, Davis L, et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke. 2003;34(6):e55. (Retrospective; 500 patients)
  112. Douglas V, Tong D, Gillum L, et al. Do the Brain Attack Co 2012alition’s criteria for stroke centers improve care for ischemic stroke? Neurology. 2005;64(3):422. (Retrospective; 15,000 patients)
  113. Gropen T, Gagliano P, Blake C, et al. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. Neurology. 2006;67(1):88. (Retrospective; 3000 patients)
  114. Stradling D, Yu W, Langdorf M, et al. Stroke care delivery before vs after JCAHO stroke center certification. Neurology. 2007;68(6):469. (Retrospective; 1200 patients)
  115. LaBresh KA, Reeves MJ, Frankel MR, et al. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program. Arch Intern Med. 2008;168(4):411-417. (Retrospective; 18,000 patients)
  116. Stoeckle-Roberts S, Reeves MJ, Jacobs BS, et al. Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project. Joint Commission Journal on Quality and Patient Safety. 2006;32(9):517-527. (Retrospective)
  117. * Meretoja A, Roine RO, Kaste M, et al. Effectiveness of Primary and Comprehensive Stroke Centers. Stroke. 2010;41(6):1102-1107. (Observational; 62,000 patients)
  118. * Xian Y, Holloway RG, Chan PS, et al. Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA. 2011;305(4):373-380. (Retrospective; 400 patients)
  119. Lichtman JH, Allen NB, Wang Y, et al. Stroke patient outcomes in US hospitals before the start of the Joint Commission Primary Stroke Center certification program. Stroke. 2009;40(11):3574-3579. (Retrospective; 367,000 patients)
  120. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011. Circulation. 2011;123(4):e18-e209. (Statistical update) 
Get Quick-Read Evidence-Based Updates
Enter your email to get free evidence-based content delivered to your inbox once per month.
Please provide a valid email address.